Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

"AN2728 (Atopic Dermatitis) - Forecast and Market Analysis to 2022" now available at Fast Market Research


Print article Print article
2014-01-10 09:11:14 - Fast Market Research recommends "AN2728 (Atopic Dermatitis) - Forecast and Market Analysis to 2022" from GlobalData, now available

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Anacor is developing AN2728, a boron-containing small molecule for the potential treatment of atopic dermatitis. AN2728 inhibits phosphodiesterase 4 (PDE4) and reduces the production of TNF-a, a precursor involved in the immune response and subsequent inflammatory process seen in atopic dermatitis.

Scope

* Overview of Atopic Dermatitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on AN2728 including product description, safety and efficacy profiles as

well as a SWOT analysis.
* Sales forecast for AN2728 for the top nine countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Full Report Details at
- www.fastmr.com/prod/760066_an2728_atopic_dermatitis_forecast_and ..

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of AN2728 performance
* Obtain sales forecast for AN2728 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
4 Disease Management
4.1 Diagnosis
4.2 Treatment Overview
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 A Systemic Drug for Severe Recalcitrant Patients
6.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach
6.2.3 A Drug that Effectively Controls Patients' Pruritus
6.2.4 Further Research into the Pathophysiology of Atopic Dermatitis
6.2.5 A Drug that Induces Disease Remission
6.2.6 Improved Quality of Life for Both Patients and their Carers
6.3 Unmet Needs Gap Analysis
6.4 Opportunities
6.4.1 Increase Treatment Armamentarium for Severe Recalcitrant Patients
6.4.2 Predictive Tests for Patient Stratification
6.4.3 More Therapeutic Options that Address Patients' Pruritus
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
8 AN2728
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
8.9 Forecast
8.9.1 Phase II Pipeline Products
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Atopic Dermatitis Patients
9.4.2 Percent Drug-treated Patients
9.4.3 General Pricing Assumptions
9.4.4 Generic Erosion
9.4.5 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Author
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms of Atopic Dermatitis
Table 2: Treatment Guidelines for Atopic Dermatitis
Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013
Table 4: Leading Treatments for Atopic Dermatitis, 2013
Table 5: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment
Table 6: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013
Table 7: Late-Stage Atopic Dermatitis Pipeline, 2013
Table 8: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013
Table 9: Product Profile - AN2728
Table 10: Efficacy Results for AN2728 in Mild to Moderate Adolescent Atopic Dermatitis Patients (Day 29)
Table 11: AN2728 SWOT Analysis, 2013
Table 12: Global Sales Forecasts ($m) for AN2728, 2012-2022
Table 13: Phase II and Phase I Atopic Dermatitis Pipeline, 2013
Table 14: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin
Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2012-2022

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com